Navigation Links
1,4-butanediol (BDO) Market is growing at a CAGR of 5.5% & to reach $7.5 Billion by 2017 - New Report by MarketsandMarkets
Date:2/17/2013

(PRWEB) February 17, 2013

The report “1,4-butanediol Market By Technology (Reppe Process, Davy process, Butadiene Process, Propylene Oxide Process & Others), Applications, & Geography: Global Industry Trends & Forecasts to 2017”, published by MarketsandMarkets, defines and segments the global 1,4-butanediol market by products with analysis and forecasting of the global volume and revenue. As of year 2012, Asia-Pacific consumed more than half of the 1,4-butanediol produced globally. The major application segments for tetrahydrofuran, polybutylene terphthalate, gamma butyrolactone, polyurethane and others; whereas tetrahydrofuran constitutes the major application segment. 1,4-butanediol is mainly produced using acetylene, maleic anhydride, butadiene, propylene oxide, etc. 1,4-butanediol is produced using Reppe technology and Davy process technology.

Browse 75+ market data tables and 25+ figures and in-depth Table of Content of “1,4-butanediol Market By Technology (Reppe Process, Davy process, Butadiene Process, Propylene Oxide Process & Others), Applications, & Geography: Global Industry Trends & Forecasts to 2017”.
http://www.marketsandmarkets.com/Market-Reports/1-4-butanediol-market-685.html
Early buyers will receive 10% customization on report.

The drivers of the industry are identified as high growth in developing regions, high demand in end-user industries, and high existing production capacities of 1,4-butanediol. Most of the production capacity of 1,4-butanediol exists in Asian region and high growth in their demand is mainly observed in developing countries. The high production capacities in the region also give flexibility to the manufacturers to scale up the production depending upon demand trends. The restraining factors are identified as raw mat
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Artificial Organs (Medical Bionic Implants) Market is expected to grow at a CAGR of 7.1% & to reach $17.82 billion by 2017 - New Report by MarketsandMarkets
2. Wafer Cleaning Market is poised to grow at a CAGR of 16.1% & to reach $5.86 billion by 2017 - New Report by MarketsandMarkets
3. Biocides Market - New Industry Research Report is Now Available for Pre-order at Transparency Market Research
4. The USPS Has Announced No Saturday Delivery and Increased Postage Again - How Does This Affect the World of Marketing?
5. Plasticizers Market - New Industry Research Report is Now Available for Pre Order at Transparency Market Research
6. Refinery Catalyst Market - New Industry Research Report is Now Available for Pre Order at Transparency Market Research
7. Amy Porterfield's FB Influence: Review Examining Facebook Marketing Course Released By WealthSpringMarketing.com
8. Supermarkets and Grocery Stores in Canada Industry Market Research Report Now Available from IBISWorld
9. Soil Treatment Market - New Industry Research Report is Now Available for Pre Order at Transparency Market Research
10. Rare Earth Metals Market - New Industry Research Report is Now Available for Pre Order at Transparency Market Research
11. Uniquely Sensitive Body Wash Skin Care Line with Native Remedy High-Grade Bentonite Detox Clay; Now Available at Whole Foods Market in San Ramon, CA.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... ... 07, 2015 , ... Nationally-renowned attorneys in the realm of ... Invokana Ketoacidosis Lawsuit Center . The website provides information on Invokana side ... wishing to learn more about Invokana lawsuits for kidney problems, ketoacidosis, heart attack, ...
(Date:7/7/2015)... ... July 07, 2015 , ... Clarion ... labels, has been featured in the latest issue of In Compliance Magazine, a ... In Compliance delivers the latest news, standards updates, technical explanations and guidance, ...
(Date:7/7/2015)... ... 2015 , ... CareSync proudly announces today that Amy Gleason, ... House as a “Champion of Change” for Precision Medicine on Wednesday, July 8th. ... Change program recognizes Gleason and eight other extraordinary individuals who are making great ...
(Date:7/7/2015)... ... 2015 , ... Each year the Holiday Inn Westbury donates many ... and international level; however, the Holiday Inn now hosts one large event at the ... the beneficiaries. In September of 2014 they hosted an event with all proceeds going ...
(Date:7/6/2015)... ... July 07, 2015 , ... Currently, mobile testing is ... AIDS, advances in the molecular diagnostic technologies, wide availability of immunosuppressive drugs and ... technologies and genetic engineering also open lucrative opportunities for the market players. , ...
Breaking Medicine News(10 mins):Health News:National Attorneys Launch Invokana Ketoacidosis Lawsuit Center 2Health News:National Attorneys Launch Invokana Ketoacidosis Lawsuit Center 3Health News:Standards Considerations for Laser Safety Labels from Clarion Safety Systems Featured in In Compliance Magazine 2Health News:Standards Considerations for Laser Safety Labels from Clarion Safety Systems Featured in In Compliance Magazine 3Health News:Standards Considerations for Laser Safety Labels from Clarion Safety Systems Featured in In Compliance Magazine 4Health News:White House names Champions of Change for Precision Medicine: CareSync COO Recognized 2Health News:White House names Champions of Change for Precision Medicine: CareSync COO Recognized 3Health News:The Holiday Inn Westbury - Long Island Will Host a Fundraising Event on September 16th 2015 from 6:00 pm - 10:00 pm to Benefit Angela's House located on Long Island 2Health News:The Holiday Inn Westbury - Long Island Will Host a Fundraising Event on September 16th 2015 from 6:00 pm - 10:00 pm to Benefit Angela's House located on Long Island 3Health News:World Infectious Disease Testing Market Examined by VPGMarketResearch.com in In-Demand Report Available at MarketPublishers.com 2Health News:World Infectious Disease Testing Market Examined by VPGMarketResearch.com in In-Demand Report Available at MarketPublishers.com 3
... team of researchers, including a number from the University of ... regions of the genome that contribute to the debilitating lung ... Their findings provide insight into the causes of the wide ... also points the way to new diagnostic markers and therapeutic ...
... , MONDAY, May 23 (HealthDay News) -- Cancer patients who ... greater sense of satisfaction about their treatment, a new study ... and accurate medical information built trust between patient and doctor. ... , the study analyzed 295 patients recently diagnosed with lymphoma, ...
... Monday, May 23, 2011 New findings out of Wake Forest ... in predicting early death in individuals with diabetes. ... Care . "People with diabetes are already at high risk ... W. Bowden, Ph.D., the director of the Center for Diabetes Research ...
... 22, 2011- Gothenburg, Sweden : The aldosterone antagonist ... new onset atrial fibrillation and flutter (AFF) in ... sub-analysis of the EMPHASIS-HF trial, presented at the ... Failure Association of the European Society of Cardiology ...
... Although chemotherapy is used to kill cancer cells, it ... such as bone marrow and blood cells, often limiting the ... Fred Hutchinson Cancer Research Center reported at today,s annual meeting ... Seattle that one possible approach to reduce this toxic effect ...
... , FRIDAY, May 20 (HealthDay News) -- The ... skin -- is significantly higher among overweight and obese kids, ... online in the Journal of Pediatrics , also found ... higher cholesterol levels, putting them at greater risk for heart ...
Cached Medicine News:Health News:Consortium identifies genome regions that could influence severity of cystic fibrosis 2Health News:Consortium identifies genome regions that could influence severity of cystic fibrosis 3Health News:Cancer Patients Benefit From Full Access to Medical Records 2Health News:Common test could help predict early death in diabetes, study shows 2Health News:Common test could help predict early death in diabetes, study shows 3Health News:EMPHASIS HF: Study shows epleronone to reduce atrial fibrillation 2Health News:EMPHASIS HF: Study shows epleronone to reduce atrial fibrillation 3Health News:Gene-modified stem cells help protect bone marrow from toxic side effects of chemotherapy 2Health News:Study Sees Link Between Psoriasis, Obesity in Kids 2
(Date:7/6/2015)... 2015 Celtaxsys, Inc., a clinical stage pharmaceutical ... rare and orphan inflammatory disease indications, announced today that ... Drug Administration (FDA) to begin a Phase 2 clinical ... adult CF patients in the US. The regulatory submissions ... will be filed soon after. This groundbreaking clinical ...
(Date:7/6/2015)... SOUTH SAN FRANCISCO, Calif. , July 6, 2015 ... leading global pharmaceutical company, and Oculeve, a development-stage medical ... eye disease, today announced that they have entered into ... an all-cash transaction.  Under the terms of the agreement, ... payment and commercialization milestone payments related to Oculeve,s lead ...
(Date:7/6/2015)... SHENZHEN, China , July 6, 2015 China ... CNIT), a leading provider of integrated cloud-based platform, exchange, ... , today announced that the Company launched its mobile ... age of accessible healthcare services on mobile devices. The ... District Health and Family Planning Bureau and Shenzhen News ...
Breaking Medicine Technology:Celtaxsys, Inc. Gains FDA Clearance for Landmark Phase 2 Trial of Anti-Inflammatory Treatment for Cystic Fibrosis (CF) 2Celtaxsys, Inc. Gains FDA Clearance for Landmark Phase 2 Trial of Anti-Inflammatory Treatment for Cystic Fibrosis (CF) 3Allergan to Acquire Oculeve Dry Eye Disease Development Programs 2Allergan to Acquire Oculeve Dry Eye Disease Development Programs 3Allergan to Acquire Oculeve Dry Eye Disease Development Programs 4CNIT Launches the Mobile App for Healthcare One Pass 2CNIT Launches the Mobile App for Healthcare One Pass 3CNIT Launches the Mobile App for Healthcare One Pass 4
... 8 Cell Therapeutics, Inc. (CTI),(Nasdaq and ... data for the,Zevalin(R) ([90Y]-ibritumomab tiuxetan) First-line Indolent ... Hematology (ASH) 50th Annual Meeting by,Morschhauser, et ... (PFS) following Zevalin consolidation therapy for patients ...
... Patients with non-valvular,atrial fibrillation receiving either 30 mg ... oral Factor Xa inhibitor, experienced comparable,safety and tolerability ... II data presented today at the 50th Annual ... Francisco. These findings are the first results,from ...
Cached Medicine Technology:Zevalin Consolidation in Patients With Complete Remission After Induction Therapy Results in Durable Remission of More Than 67 Months 2Zevalin Consolidation in Patients With Complete Remission After Induction Therapy Results in Durable Remission of More Than 67 Months 3Zevalin Consolidation in Patients With Complete Remission After Induction Therapy Results in Durable Remission of More Than 67 Months 4Zevalin Consolidation in Patients With Complete Remission After Induction Therapy Results in Durable Remission of More Than 67 Months 5New Phase II Data Show Safety of Once-Daily Oral Factor Xa Inhibitor, DU-176b, Comparable to Warfarin in Patients With Non-Valvular Atrial Fibrillation 2New Phase II Data Show Safety of Once-Daily Oral Factor Xa Inhibitor, DU-176b, Comparable to Warfarin in Patients With Non-Valvular Atrial Fibrillation 3New Phase II Data Show Safety of Once-Daily Oral Factor Xa Inhibitor, DU-176b, Comparable to Warfarin in Patients With Non-Valvular Atrial Fibrillation 4New Phase II Data Show Safety of Once-Daily Oral Factor Xa Inhibitor, DU-176b, Comparable to Warfarin in Patients With Non-Valvular Atrial Fibrillation 5
... white LED (Light Emitting Diode) light source, coupled ... the freedom of using a slit lamp anywhere ... about 1.5 lbs. (0.68 kg) with its battery ... Its ergonomic, portable design and convenient carrying ...
Powerful LED Illumination , The ultrabright and compact 3S LED HeadLight from HEINE for Powerful, coaxial illumination...
... Abnormal Control Serum is intended for monitoring the ... assays. It is for in vitro diagnostic use ... format, the control offers up to ten days ... control is to be used in accordance with ...
e-MDs Bill practice management system is used in the medical billing cycle....
Medicine Products: